Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.

Main trial objectives are to determine whether - INT-747 (25 mg/day) improves insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD) - INT-747 alters hepatic and/or white adipose tissue (WAT) lipase activity and fatty acid/triglyceride (FA/TG) content in NAFLD - INT-747 improves hepatobiliary transporter expression in NAFLD and gallstone disease - INT-747 improves biliary lipid profiles towards lower cholesterol saturation